Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
XERS
↓ PDF (Pro)Xeris Biopharma Holdings Inc. Common Stock
HealthcareDrug Manufacturers - Specialty & GenericUnited StatesNASDAQ
$6.43
+3.13%today
MKT CAP
$1.1B
+6.3% · 1Y
Earnings History
-50.0%
+66.7%
-100.0%
+33.3%
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Analyst Targets
Current price
$6.43
Low
$8.00
Analyst Mean
$11.14
High
$18.00
7 analystsStrong Buy
Full Financials
Trailing P/E94.7x
Forward P/E17.0x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ+15.4%
5y Revenue CAGR+38.3%
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership3.4%
Institutional Ownership59.3%
Short % of Float9.43%
Days to Cover9.4d
1 Week+3.1%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| HECHT BETH P | Officer | Sale | 16,667 | $6.23 | $0.10M | 2026-05-01 |
| HECHT BETH P | Officer | Sale | 16,667 | $5.99 | $0.10M | 2026-04-01 |
| BRADY JAMES ALOYSIUS | Director | Sale | 10,834 | $5.54 | $0.06M | 2026-03-30 |
| MCCULLOCH KEVIN | President | Conversion | 48,898 | $3.94 | $0.20M | 2026-03-12 |
| PIEPER STEVEN | Chief Financial Officer | Conversion | 41,927 | $4.09 | $0.20M | 2026-03-05 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| Blackrock Inc. | institution | 7.32% | $0.08B | +5.97% | 2025-12-31 |
| Vanguard Group Inc | institution | 6.48% | $0.07B | +13.83% | 2025-12-31 |
| Shaw D.E. & Co., Inc. | institution | 4.39% | $0.05B | +29.71% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 2.87% | $0.03B | +5.27% | 2025-12-31 |
| Geode Capital Management, LLC | institution | 2.48% | $0.03B | +3.28% | 2025-12-31 |
| State Street Corporation | institution | 2.38% | $0.03B | +10.13% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | fund | 2.22% | $0.02B | +2.46% | 2026-03-31 |
| Qube Research & Technologies Ltd | institution | 2.03% | $0.02B | +6.82% | 2025-12-31 |
| Driehaus Capital Management, LLC | institution | 1.73% | $0.02B | +13.80% | 2025-12-31 |
| Nuveen, LLC | institution | 1.69% | $0.02B | +3.91% | 2026-03-31 |
| Morgan Stanley | institution | 1.57% | $0.02B | -15.90% | 2025-12-31 |
| Wellington Management Group, LLP | institution | 1.32% | $0.01B | +293.59% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 1.04% | $0.01B | +3.93% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | fund | 0.86% | $0.01B | -1.39% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | fund | 0.75% | $0.01B | +1.43% | 2026-03-31 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | fund | 0.71% | $0.01B | -1.87% | 2026-01-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | fund | 0.57% | $0.01B | +10.65% | 2026-03-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | fund | 0.50% | $0.01B | +0.68% | 2026-02-28 |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | fund | 0.46% | $0.00B | +3.25% | 2026-02-28 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | fund | 0.44% | $0.00B | +1.02% | 2026-02-28 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| ALVO | $1.1B | 42 | 35.1 | 19.2 | - | - | - | - | 0.00% |
| AMPH | $1.1B | 100 | 11.8 | 6.9 | - | - | - | - | 0.00% |
| EVO | $1.2B | 5 | - | - | - | - | - | - | 0.00% |
| COLL | $1.2B | 82 | 22.7 | 5.6 | - | - | - | - | 0.00% |
| CRON | $990M | 5 | - | - | - | - | - | - | 0.00% |
| PCRX | $937M | 58 | 193.0 | 7.0 | - | - | - | - | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for XERS.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.